Abegaz Fentaw (PhD)Anagaw A.Berhanu2018-06-252023-11-092018-06-252023-11-092009-06http://10.90.10.223:4000/handle/123456789/3126Highly active antiretroviral therapy (HAART) has significantly reduced mortality caused by human immuno-deficiency virus (HIV) by enhancing the physiological and immunological ability to counterattack against the virus and increases the life expectancy. Once started, the antiretroviral treatment should be continued lifelong and adherence to this treatment should be nearly perfect to enable long-term efficacy. A continuous and life-long treatment with HAART may lead to a broad spectrum of significant toxicities. As a result many patients interrupt their HAART without the knowledge and advice of the clinicians and this cause the patient immune to degrade and even cause to death. Therefore, this study is an attempt to examine the predictive factors of interruption duration in patients who interrupt their ARV drugs treatment. The study is a retrospective cohort study of HIV/AIDS patients under HAART but discontinued their treatment for at least one month, which comprises a total of 723 patients from Zewditu Memorial Hospital. Of these patients about 67% resumed their treatment. In the analysis of data the Kaplan-Meier survival estimator and Cox proportional hazards regression model are used. Based on the data analysis, it is found that main effects: education, baseline age, baseline weight, CD4 count at the start of HAART and prior to interruption, duration on HAART and interaction effects: marital status with disease duration and marital status with sex are important factors that are related to time to resumption of HAART. In general, HIV/AIDS patients who have prolonged treatment interruption are characterized by having lower level of education, younger age, high weight, higher CD4 count at the start of HAART, lower CD4 count prior to treatment interruption, longer duration on treatment follow-up and currently not married and male patients with longer disease durationenResumption for Chronic Hiv-1 PatientsThesis